Janssen's IMBRUVICA(R) (ibrutinib) receives positive CHMP opinion for expanded use
Janssen-Cilag announced the CHMP of the European Medicines Agency has adopted a Positive Opinion, recommending broadening the existing marketing authorisation for ibrutinib as a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia. April 29, 2016